JZP 258Alternative Names: JZP-258; Oxybate mixed salt solution – Jazz Pharmaceuticals; Oxybate – Jazz Pharmaceuticals
Latest Information Update: 12 Nov 2016
At a glance
- Originator Jazz Pharmaceuticals Inc
- Class Hydroxybutyrates; Sleep disorder therapies; Small molecules
- Mechanism of Action Dopamine receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Cataplexy; Narcolepsy
Most Recent Events
- 02 Nov 2016 Phase-III clinical trials in Cataplexy and Narcolepsy in Czech Republic and Spain (PO) (EudraCT2016-000426-20)